|
|
|
|
|
Reboxetine
drug data and news
Reboxetine drug data, resources, and news articles (when available). Onconews.org provides news on cancer research. This section, which includes profiles on medicines that may or not be cancer-related is in beta form. If things run smoothly we will be releasing a new format late in the summer of 2006.
|
| Generic name | Reboxetine | ||
| Brand Names/Synonyms | Edronax; Norebox; Reboxetine; Reboxetine [Inn]; Reboxetinemesylate; Vestra | ||
| Indication | For the treatment of clinical depression. | ||
| Sponsored links | Description | Not Available | |
| Pharmacology | Reboxetine is a selective noradrenaline reuptake inhibitor (NaRI), the first drug of new antidepressant class. Reboxetine is an a-ariloxybenzyl derivative of morpholine. Reboxetine is primarily used to treat depression but has also been found useful in the treatment of narcolepsy and panic disorders. | ||
| Mechanism Of Action | Reboxetine is a selective inhibitor of noradrenaline reuptake. It inhibits noradrenaline reuptake in vitro to a similar extent to the tricyclic antidepressant desmethylimipramine. Reboxetine does not affect dopamine or serotonin reuptake and it has low in vivo and in vitro affinity for adrenergic, cholinergic, histaminergic, dopaminergic and serotonergic receptors. | ||
| Reboxetine News (When available) |
| ||
| Dosage Forms | TABLET | ||
| Drug_Category | Antidepressants; ATC:N06AX18 | ||
| Absorption | Reboxetine is rapidly and extensively absorbed following oral administration. | ||
| Interactions |
Interactions for Reboxetine: Combined usage of MAO inhibitors should be avoided | ||
| Toxicity | Reports of seizures (rare) have been reported | ||
| Organisms Affected | Humans and other mammals | ||
| Chemical IUPAC Name | 2-[(2-ethoxyphenoxy)-phenyl-methyl]morpholine | ||
| Chemical Formula | C19H23NO3 | ||
| Molecular Weight | 313.391 g/mol | ||
| Smiles String | CCOC1=CC=CC=C1OC(C2CNCCO2)C3=CC=CC=C3 | ||
| Melting Point | 170-171 oC (Mesylate salt) | ||
| Water Solubility | 8 mg/mL (Mesylate salt) | ||
| State | Solid | ||
| LogP/Hphobicity | 0.48 (Ding, YS et al. J. Neruochem. 94:1471 (2005)) | ||
| Isoelectric Point | Not Available | ||
| Biotransformation | Reboxetine is metabolized by dealkylation, hydroxylation and oxidation followed by glucuronide or sulphate conjugation. It is metabolized by the cytochrome P450 CYP isoenzyme 3A4. | ||
| Half Life | 12.5 hours | ||
| Protein Binding [%] | 98% | ||
| RxList Link | Not Available>RXlist | ||
| Sponsored links | |||
| Drug Reference | Not Available | ||
| Drug Type | Approved Drug | ||
| Accession No | APRD00198 | ||
| CAS Registry Number | 98769-81-4 | ||
| KEGG Compound ID | Not Available | ||
| PubChem ID | SID:207897 | ||
| PharmGKB ID | Not Available | ||
| SwissProt ID | Not Available | ||
| GenBank ID | Not Available | ||
| Drug ID Number [DIN] | Not Available |
|
Home | About | Cancers | Treatment | Medications Copyright onconews.org 2005. All Rights Reserved. |